Takeda to Buy IDM Pharma for $2.64/Share
The acquisition price is a 55% premium to IDM Pharma's closing price on Friday.
Takeda Pharmaceutical
of Japan has agreed to acquire
IDM Pharma
(IDMI)
Scroll to Continue
TheStreet Recommends
for $2.64 a share, or close to about $70 million.
The acquisition price represents a 55% premium to the closing price Friday of IDM Pharma of $1.70.
IDM Pharma recently received European marketing approval for Mepact, a therapy indicated for the treatment of non-metastatic osteosarcoma, or malignant bone cancer, in children, adolescents and young adults.
